Previous close | 25.50 |
Open | 29.85 |
Bid | 28.70 |
Ask | 29.60 |
Strike | 120.00 |
Expiry date | 2022-08-19 |
Day's range | 29.85 - 29.85 |
Contract range | N/A |
Volume | |
Open interest | 3 |
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).